Dissecting aneuploidy phenotypes by constructing Sc2.0 chromosome VII and SCRaMbLEing synthetic disomic yeast
- PMID: 38020968
- PMCID: PMC10667312
- DOI: 10.1016/j.xgen.2023.100364
Dissecting aneuploidy phenotypes by constructing Sc2.0 chromosome VII and SCRaMbLEing synthetic disomic yeast
Abstract
Aneuploidy compromises genomic stability, often leading to embryo inviability, and is frequently associated with tumorigenesis and aging. Different aneuploid chromosome stoichiometries lead to distinct transcriptomic and phenotypic changes, making it helpful to study aneuploidy in tightly controlled genetic backgrounds. By deploying the engineered SCRaMbLE (synthetic chromosome rearrangement and modification by loxP-mediated evolution) system to the newly synthesized megabase Sc2.0 chromosome VII (synVII), we constructed a synthetic disomic yeast and screened hundreds of SCRaMbLEd derivatives with diverse chromosomal rearrangements. Phenotypic characterization and multi-omics analysis revealed that fitness defects associated with aneuploidy could be restored by (1) removing most of the chromosome content or (2) modifying specific regions in the duplicated chromosome. These findings indicate that both chromosome copy number and specific chromosomal regions contribute to the aneuploidy-related phenotypes, and the synthetic chromosome resource opens new paradigms in studying aneuploidy.
Keywords: SCRaMbLE; aneuploidy phenotypes; aneuploidy recovery approaches; growth rate; synVII; synthetic disomic yeast; synthetic genomics.
© 2023 The Authors.
Conflict of interest statement
J.D.B. is a founder and director of CDI Labs, Inc.; a founder of and consultant to Neochromosome, Inc.; and a founder and scientific advisory board member of and consultant to ReOpen Diagnostics, LLC. J.D.B. serves or served on the scientific advisory board of the following: Logomix, Inc., Sangamo, Inc., Modern Meadow, Inc., Rome Therapeutics, Inc., Sample6, Inc., Tessera Therapeutics, Inc., and the Wyss Institute. J.S.B. is a founder of Neochromsome, Inc.; is a consultant to Opentrons Labworks, Inc.; and serves on the scientific advisory board of Reflexion Pharmaceuticals, Inc.
Figures






References
-
- Baker D.J., Dawlaty M.M., Wijshake T., Jeganathan K.B., Malureanu L., van Ree J.H., Crespo-Diaz R., Reyes S., Seaburg L., Shapiro V., et al. Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan. Nat. Cell Biol. 2013;15:96–102. doi: 10.1038/ncb2643. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources